table1_Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.xlsx (65.68 kB)
Download file

table1_Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.xlsx

Download (65.68 kB)
dataset
posted on 25.01.2021, 04:12 by Catherine Z. Chen, Paul Shinn, Zina Itkin, Richard T. Eastman, Robert Bostwick, Lynn Rasmussen, Ruili Huang, Min Shen, Xin Hu, Kelli M. Wilson, Brianna M. Brooks, Hui Guo, Tongan Zhao, Carleen Klump-Thomas, Anton Simeonov, Samuel G. Michael, Donald C. Lo, Matthew D. Hall, Wei Zheng

Drug repurposing is a rapid approach to identify therapeutics for the treatment of emerging infectious diseases such as COVID-19. To address the urgent need for treatment options, we carried out a quantitative high-throughput screen using a SARS-CoV-2 cytopathic assay with a compound collection of 8,810 approved and investigational drugs, mechanism-based bioactive compounds, and natural products. Three hundred and nineteen compounds with anti-SARS-CoV-2 activities were identified and confirmed, including 91 approved drugs and 49 investigational drugs. The anti-SARS-CoV-2 activities of 230 of these confirmed compounds, of which 38 are approved drugs, have not been previously reported. Chlorprothixene, methotrimeprazine, and piperacetazine were the three most potent FDA-approved drugs with anti-SARS-CoV-2 activities. These three compounds have not been previously reported to have anti-SARS-CoV-2 activities, although their antiviral activities against SARS-CoV and Ebola virus have been reported. These results demonstrate that this comprehensive data set is a useful resource for drug repurposing efforts, including design of new drug combinations for clinical trials for SARS-CoV-2.

History

References